<DOC>
	<DOCNO>NCT01990989</DOCNO>
	<brief_summary>The aim present study evaluate candidate variable , include Cytochrome P450 2C19 ( CYP2C19 ) genotype , clinical demographic variable , establish simple risk score easily adopt clinician identify patient risk HPR composite cardiovascular outcome Chinese Han patient treat dual antiplatelet therapy .</brief_summary>
	<brief_title>Clopidogrel Pharmacogenetic Score System</brief_title>
	<detailed_description>There large inter-individual variability biological antiplatelet responsiveness patient treat clopidogrel . Our previous study suggest clopidogrel treat Chinese patient acute coronary syndrome ( ACS ) , carrier least one CYP2C19 loss-of-function allele could predict great risk high on-treatment platelet reactivity ( HPR ) , impact mainly attribute CYP2C19*2 . But know , CYP2C19*2 could explain small proportion variability . Various clinical demographic variable consider influence response antiplatelet therapy . Study objectives : The present study aim evaluate candidate variable , include CYP2C19 gene polymorphism , clinical demographic variable , establish simple risk score identify patient risk HPR composite cardiovascular outcome . Study design : Step 1 : Population enrollment medication This mono-center study conduct General Hospital Chinese People 's Liberation Army . Consecutive patient 18 year old admit ACS recruit give informed consent . After admission , enrol patient treat 100 mg aspirin 75mg clopidogrel per day . A load dose 300 mg clopidogrel give patient undergo coronary angiography . Step 2 : Clinical demographic data collection A detailed demographic medical data extract medical chart prescription record . For development risk score system , choose variable available routine clinical practice . Clinical candidate variable include smoke history , diabetes , hypertension , renal failure serum creatinine &gt; 1.5mg/dL-1 , hypercholesterolemia , leave ventricular dysfunction , age , gender , acute coronary syndrome admission co-medication statin , calcium channel inhibitor , proton pump inhibitor . Step 3 : Platelet function measurement Genotyping After 5 day maintenance dose clopidogrel administration , blood sample draw light transmittance aggregometry ( LTA ) testing , use APACT-4 aggregometer ( LABiTec , Germany ) . The magnitude on-treatment platelet reactivity quantify use LTA 20Âµmol/L ADP ( adenosine disphosphate ) agonist . Aggregation express maximal percentage change light transmittance baseline , platelet-poor plasma reference . Genomic DNA extract peripheral blood leucocyte patient . The loss function allele , CYP2C19*2 ( rs4244285 ) CYP2C19*3 ( rs4986893 ) , genotyped polymerase chain reaction ( PCR ) -ligase detection reaction ( LDR ) sequence method . Step 4 : Follow-up At one year , incidence composite cardiovascular outcome assess review patients'charts re-admission telephone interview . Telephone interviewer blind respect result platelet aggregation genotype . Step 5 : Statistical analysis development risk score Logistic regression Cox proportional hazard survival regression use develop risk score system candidate variable include clinical demographic variable , CYP2C19 genotype , platelet aggregation .</detailed_description>
	<mesh_term>Acute Coronary Syndrome</mesh_term>
	<mesh_term>Clopidogrel</mesh_term>
	<mesh_term>Ticlopidine</mesh_term>
	<criteria>Inclusion criterion : Patients 18 year old Admitted ACS Department Geriatric Cardiology , General Hospital Chinese People 's Liberation Army The diagnosis ACS accord American Heart Association/American College Cardiology ( AHA/ACC ) criterion , 2012 Exclusion criterion : Known contraindication dual antiplatelet therapy History chronic inflammatory disease Steroidal nonsteroidal antiinflammatory drug use Previous administration antiplatelet drug within 1 month coronary artery angiography Illicit drug abuse Significant bleeding tendency Cerebrovascular event within 3months Major surgery within 4 week</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>November 2013</verification_date>
	<keyword>clopidogrel</keyword>
	<keyword>pharmacogenomics</keyword>
	<keyword>CYP2C19</keyword>
	<keyword>platelet aggregation</keyword>
	<keyword>score system</keyword>
	<keyword>ischemic cardiovascular outcome</keyword>
	<keyword>hemorrhage complication</keyword>
</DOC>